Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASL
02 October 2009 - 6:05AM
PR Newswire (US)
CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral diseases, today announced that two abstracts on
IDX184, the company's lead hepatitis C development program, have
been accepted for presentation at the 60th Annual Meeting of the
American Association for the Study of Liver Diseases (AASLD,
October 30-November 3, 2009 in Boston, Massachusetts). Full
abstracts can now be viewed at the AASLD website at
http://www.aasld.org/. The accepted abstracts are as follows: --
Lalezari, et al, "Antiviral Activity, Safety and Pharmacokinetics
of IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor, in
Patients with Chronic Hepatitis C", will be presented in a
late-breaking poster session on Monday, November 2 between 8:00
a.m. - 5:30 p.m. -- Lallos, et al, "Combination of IDX184, a
Nucleotide Prodrug Polymerase Inhibitor, With Other Classes of HCV
Inhibitors is Additive to Synergistic in the HCV Replicon In Vitro"
will be presented in a poster session entitled HCV Therapy:
Preclinical and Clinical Development on Tuesday, November 3, 2009
between 8:00 a.m. - 1:00 p.m. About Idenix Idenix Pharmaceuticals,
Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral diseases. Idenix's
current focus is on the treatment of infections caused by hepatitis
C virus. For further information about Idenix, please refer to
http://www.idenix.com/. Forward-looking Statements This press
release contains "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995. Such forward-
looking statements can be identified by the use of forward-looking
terminology such as "will" or similar expressions, or by express or
implied statements with respect to the company's clinical
development programs or commercialization activities in hepatitis
C. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. In
particular, management's expectations could be affected by
unexpected regulatory actions or delays; uncertainties relating to,
or unsuccessful results of, clinical trials, including additional
data relating to the ongoing clinical trials evaluating its product
candidates; the company's ability to obtain additional funding
required to conduct its research, development and commercialization
activities; the company's dependence on third party collaborators,
changes in the company's business plan or objectives; the ability
of the company to attract and retain qualified personnel;
competition in general; and the company's ability to obtain,
maintain and enforce patent and other intellectual property
protection for its product candidates and its discoveries. These
and other risks which may impact management's expectations are
described in greater detail under the caption "Risk Factors" in the
company's Quarterly Report on Form 10-Q for the quarter ended June
30, 2009 as filed with the Securities and Exchange Commission (SEC)
and other filings that the company makes with the SEC. All
forward-looking statements reflect the company's expectations only
as of the date of this release and should not be relied upon as
reflecting the company's views, expectations or beliefs at any date
subsequent to the date of this release. Idenix anticipates that
subsequent events and developments may cause these views,
expectations and beliefs to change. However, while Idenix may elect
to update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. Idenix
Pharmaceuticals Contact: Teri Dahlman (617) 995-9905 DATASOURCE:
Idenix Pharmaceuticals, Inc. CONTACT: Teri Dahlman of Idenix
Pharmaceuticals, +1-617-995-9905 Web Site: http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More Idenix Pharmaceuticals (MM) News Articles